TOKYO -- Japanese materials manufacturer AGC will boost production by 50% of a crucial agent in a coronavirus vaccine candidate under development by U.S. firm Novavax.
Pharmaceuticals
Japan's AGC to expand vaccine agent production for Novavax
US biotechnology firm to produce billions of doses by end of 2021
AGC Biologics, based in the U.S. city of Seattle, will supply an ingredient for Novavax's coronavirus vaccine candidate. (Photo courtesy of AGC)
Read Next
Latest on Pharmaceuticals
